NO20076480L - Fenyl-3-{(3-(1H-pyrrol-2-yl)-[1,2,4]oksadiazol-5-yl]piperidin-1-yl} metanonderivater og beslektede forbindelser som positive allosteriske modulatorer av metatrofe glutamatreseptorer - Google Patents

Fenyl-3-{(3-(1H-pyrrol-2-yl)-[1,2,4]oksadiazol-5-yl]piperidin-1-yl} metanonderivater og beslektede forbindelser som positive allosteriske modulatorer av metatrofe glutamatreseptorer

Info

Publication number
NO20076480L
NO20076480L NO20076480A NO20076480A NO20076480L NO 20076480 L NO20076480 L NO 20076480L NO 20076480 A NO20076480 A NO 20076480A NO 20076480 A NO20076480 A NO 20076480A NO 20076480 L NO20076480 L NO 20076480L
Authority
NO
Norway
Prior art keywords
metatrophic
oxadiazol
pyrrol
piperidin
phenyl
Prior art date
Application number
NO20076480A
Other languages
English (en)
Inventor
Giovanni Palombi
Emmanuel Le Poul
Stefania Gagliardi
Jean-Philippe Rocher
Sonia Maria Poli
Iain Lingard
Original Assignee
Addex Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Addex Pharma Sa filed Critical Addex Pharma Sa
Publication of NO20076480L publication Critical patent/NO20076480L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Den foreliggende oppfinnelse vedrører nye forbindelser som er pyrrol-derivater med formel (I) hvori A, B, P, Q,W, Ri og R2 er definert i beskrivelsen. Forbindelsene ifølge oppfinnelsen er anvendelige ved forebygging eller behandling av sentrale eller perifere nervesystem-sykdommer så vel som andre sykdommer som moduleres ved mGluR5-reseptorer.
NO20076480A 2005-05-18 2007-12-17 Fenyl-3-{(3-(1H-pyrrol-2-yl)-[1,2,4]oksadiazol-5-yl]piperidin-1-yl} metanonderivater og beslektede forbindelser som positive allosteriske modulatorer av metatrofe glutamatreseptorer NO20076480L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0510141.5A GB0510141D0 (en) 2005-05-18 2005-05-18 Novel compounds B3
PCT/IB2006/002047 WO2006123257A2 (en) 2005-05-18 2006-05-17 Phenyl-3-{(3-(1h-pyrrol-2-yl)-[1, 2 , 4]0xadiaz0l-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors

Publications (1)

Publication Number Publication Date
NO20076480L true NO20076480L (no) 2008-01-28

Family

ID=34708379

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076480A NO20076480L (no) 2005-05-18 2007-12-17 Fenyl-3-{(3-(1H-pyrrol-2-yl)-[1,2,4]oksadiazol-5-yl]piperidin-1-yl} metanonderivater og beslektede forbindelser som positive allosteriske modulatorer av metatrofe glutamatreseptorer

Country Status (24)

Country Link
US (1) US20090203737A1 (no)
EP (1) EP1912979B1 (no)
JP (2) JP2008540637A (no)
KR (1) KR20080014046A (no)
CN (1) CN101218234B (no)
AT (1) ATE513828T1 (no)
AU (1) AU2006248657B2 (no)
BR (1) BRPI0610059A2 (no)
CA (1) CA2608324A1 (no)
CY (1) CY1111859T1 (no)
DK (1) DK1912979T3 (no)
EA (1) EA014081B1 (no)
ES (1) ES2367663T3 (no)
GB (1) GB0510141D0 (no)
HK (1) HK1112909A1 (no)
IL (1) IL187187A0 (no)
MX (1) MX2007014403A (no)
NO (1) NO20076480L (no)
NZ (1) NZ564202A (no)
PL (1) PL1912979T3 (no)
PT (1) PT1912979E (no)
UA (1) UA92494C2 (no)
WO (1) WO2006123257A2 (no)
ZA (1) ZA200710279B (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540635A (ja) * 2005-05-18 2008-11-20 アデックス ファーマ ソシエテ アノニム 代謝型グルタミン酸受容体の正のアロステリック調節因子としての置換されたオキシジアゾール誘導体
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds
EA201070143A1 (ru) 2007-07-13 2010-08-30 Аддекс Фарма С.А. Новые гетероароматические производные и их использование в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
JP5465177B2 (ja) 2007-09-20 2014-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性のモジュレーターとしての化合物および組成物
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2393780A1 (en) * 2009-02-04 2011-12-14 Recordati Ireland Limited Heterocyclic derivatives as m-glu5 antagonists
US20100222381A1 (en) 2009-02-27 2010-09-02 Hariprasad Vankayalapati Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
AU2010239253A1 (en) * 2009-04-23 2011-11-24 Merck Sharp & Dohme Corp. 2-alkyl piperidine mGluR5 receptor modulators
GB0912946D0 (en) 2009-07-24 2009-09-02 Addex Pharmaceuticals Sa New compounds 5
WO2011075699A2 (en) 2009-12-18 2011-06-23 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
PL2712358T3 (pl) 2011-05-13 2017-05-31 Array Biopharma, Inc. Związki mocznika pirolidynowego, tiomocznika pirolidynowego oraz guanidyny pirolidynowej jako inhibitory kinazy trka
AU2012296662A1 (en) 2011-08-15 2014-03-27 Intermune, Inc. Lysophosphatidic acid receptor antagonists
ES2797123T3 (es) 2011-12-21 2020-12-01 Novira Therapeutics Inc Agentes antivirales para la hepatitis B
NZ743463A (en) 2012-08-28 2019-09-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
SG11201503731SA (en) 2012-11-13 2015-06-29 Array Biopharma Inc Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
KR102181915B1 (ko) 2012-11-13 2020-11-23 어레이 바이오파마 인크. Trka 키나아제 억제제로서 n-피롤리디닐, n'-피라졸릴-우레아, 티오우레아, 구아니딘 및 시아노구아니딘 화합물
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
WO2014078408A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9546156B2 (en) 2012-11-13 2017-01-17 Array Biopharma Inc. N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078378A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
SI2961732T1 (sl) 2013-02-28 2017-07-31 Janssen Sciences Ireland Uc Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
AP2015008968A0 (en) 2013-07-25 2015-12-31 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives andthe use thereof as medicaments for the treatment of hepatitis b
DK3060547T3 (en) 2013-10-23 2018-01-15 Janssen Sciences Ireland Uc CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
EA035848B1 (ru) 2014-02-06 2020-08-20 Янссен Сайенсиз Айрлэнд Юси Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
NZ727418A (en) 2014-05-15 2023-03-31 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
JP2018510159A (ja) 2015-03-19 2018-04-12 ノヴィラ・セラピューティクス・インコーポレイテッド アゾカン及びアゾナン誘導体及びｂ型肝炎感染症の治療法
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
TW201718496A (zh) 2015-09-29 2017-06-01 諾維拉治療公司 B型肝炎抗病毒劑之晶型
AU2017248828A1 (en) 2016-04-15 2018-11-01 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN112955435A (zh) 2018-10-24 2021-06-11 吉利德科学公司 Pd-1/pd-l1抑制剂
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE
KR20210130753A (ko) 2019-02-22 2021-11-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체
JP2022532526A (ja) 2019-05-06 2022-07-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｈｂｖ感染又はｈｂｖ誘導性疾患の処置において有用なアミド誘導体
IL293592A (en) 2019-12-06 2022-08-01 Vertex Pharma Transduced tetrahydrofurans as sodium channel modulators
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer
WO2022069953A1 (en) * 2020-09-29 2022-04-07 Ranjith Siddaraj Synthesis and characterization of (s)-3-(5- fluoropyridin-2-yl)-5-(piperidin-3-yl)-l,2,4-oxadiazole derivatives and their secretory phospholipase a2 (spla2) inhibitor activity
AR126073A1 (es) 2021-06-04 2023-09-06 Vertex Pharma N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509153A (en) * 1967-03-24 1970-04-28 Miles Lab 5-phenyl (or 5-phenylalkyl)-2-(omega-(4-phenyl-1-piperazinyl)alkyl)tetrazoles
US3991064A (en) * 1975-01-17 1976-11-09 Warner-Lambert Company Benzonaphthyridines
US3966748A (en) * 1975-05-08 1976-06-29 American Cyanamid Company Para-fluorophenyl-N-heterocyclic substituted butanes
US5338969A (en) * 1991-06-27 1994-08-16 Texas Instruments, Incorporated Unerasable programmable read-only memory
US6846839B1 (en) * 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
GB9603755D0 (en) * 1996-02-22 1996-04-24 Pfizer Ltd Therapeutic agents
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
AU2935200A (en) * 1999-04-30 2000-11-17 Pfizer Products Inc. Compounds for the treatment of obesity
TR200201568T2 (tr) * 1999-12-16 2002-10-21 Schering Corporation İkame edilmiş imidazol nöropeptid Y Y5 reseptörü antagonistleri.
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
HU229553B1 (en) * 2000-06-12 2014-01-28 Eisai R & D Man Co 1,2-dihydropyridine compound, process for preparation of the same and use thereof
AU2001272476A1 (en) * 2000-06-16 2001-12-24 Smithkline Beecham Plc Piperidines for use as orexin receptor antagonists
US6894063B2 (en) * 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
US6946476B2 (en) * 2000-12-21 2005-09-20 Schering Corporation Heteroaryl urea neuropeptide Y Y5 receptor antagonists
MXPA04002661A (es) * 2001-09-21 2004-11-22 Sanofi Aventis Derivados de pirimidona 4, 3-sustituida.
AU2002337499B2 (en) * 2001-09-21 2007-08-23 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
WO2003029210A2 (en) * 2001-10-04 2003-04-10 Merck & Co. Inc. Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
EP1452525A4 (en) * 2001-10-30 2005-01-26 Nippon Shinyaku Co Ltd AMIDE DERIVATIVES AND CORRESPONDING MEDICAMENTS
US6806279B2 (en) * 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
WO2003093236A1 (en) * 2002-05-02 2003-11-13 Euro-Celtique, S.A. 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor
CA2484209C (en) * 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
WO2004014902A2 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
MXPA05005583A (es) * 2002-11-26 2005-07-27 Pfizer Prod Inc Activadores de ppar.
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
DE602004017316D1 (de) * 2003-07-24 2008-12-04 Euro Celtique Sa Heteroaryl-tetrahydropyridylverbindungen, die sich für die behandlung bzw. die prävention von schmerzen eignen
KR101222364B1 (ko) * 2003-08-25 2013-01-15 트로비스 파마슈티칼스 엘엘씨 치환된 8-헤테로아릴 크산틴
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
FR2865733B1 (fr) * 2004-02-04 2007-10-12 Merck Sante Sas Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine
CN1956719A (zh) * 2004-05-25 2007-05-02 辉瑞产品公司 用于治疗负能量平衡的特定 ppar激动剂
PT1805164E (pt) * 2004-09-29 2011-04-11 Sanofi Aventis Derivados de 6-(piridinil)-4-pirimidona como inibidores de proteína-cinase tau 1
JP2008516962A (ja) * 2004-10-15 2008-05-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管傷害を治療する方法
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
EP1809620B1 (en) * 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
US7713998B2 (en) * 2004-11-10 2010-05-11 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic compound and pharmaceutical use thereof
WO2006065601A2 (en) * 2004-12-15 2006-06-22 Merck & Co., Inc. Inhibitors of akt activity
JP2008540635A (ja) * 2005-05-18 2008-11-20 アデックス ファーマ ソシエテ アノニム 代謝型グルタミン酸受容体の正のアロステリック調節因子としての置換されたオキシジアゾール誘導体
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds

Also Published As

Publication number Publication date
PL1912979T3 (pl) 2011-11-30
DK1912979T3 (da) 2011-08-22
AU2006248657A1 (en) 2006-11-23
ATE513828T1 (de) 2011-07-15
CN101218234B (zh) 2011-12-14
WO2006123257A8 (en) 2007-03-15
NZ564202A (en) 2011-04-29
EA014081B1 (ru) 2010-08-30
JP2008540637A (ja) 2008-11-20
HK1112909A1 (en) 2008-09-19
KR20080014046A (ko) 2008-02-13
ES2367663T3 (es) 2011-11-07
MX2007014403A (es) 2008-04-21
AU2006248657B2 (en) 2012-07-19
EP1912979A2 (en) 2008-04-23
IL187187A0 (en) 2008-02-09
WO2006123257A2 (en) 2006-11-23
UA92494C2 (ru) 2010-11-10
EP1912979B1 (en) 2011-06-22
US20090203737A1 (en) 2009-08-13
CN101218234A (zh) 2008-07-09
EA200702470A1 (ru) 2008-06-30
CY1111859T1 (el) 2015-11-04
WO2006123257A3 (en) 2007-05-03
BRPI0610059A2 (pt) 2010-05-25
ZA200710279B (en) 2009-03-25
JP2012184254A (ja) 2012-09-27
CA2608324A1 (en) 2006-11-23
GB0510141D0 (en) 2005-06-22
PT1912979E (pt) 2011-08-22

Similar Documents

Publication Publication Date Title
NO20076480L (no) Fenyl-3-{(3-(1H-pyrrol-2-yl)-[1,2,4]oksadiazol-5-yl]piperidin-1-yl} metanonderivater og beslektede forbindelser som positive allosteriske modulatorer av metatrofe glutamatreseptorer
MX2007014444A (es) Derivados de oxadiazol sustituido como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
WO2006123249A3 (en) Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
ATE493397T1 (de) Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
WO2005123703A3 (en) Alkynyl derivatives as modulators of metabotropic glutamate receptors
MX2007014400A (es) Novedosos compuestos heterociclicos como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
HK1128919A1 (en) Allosteric modulators of metabotropic glutamate receptors
EA200602179A1 (ru) Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств
NO20083584L (no) Bensoyl-piperidin derivater som 5HT2/D3 modulatorer
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
NO20082174L (no) 3,5-disubstituerte fenylpiperidiner som modulatorer av dopamin-neurotransmisjon
ATE486071T1 (de) Azabicycloä3.1.0ühexan-derivate als modulatoren des dopamin-d3-rezeptors
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
DE602007013467D1 (de) 4,5,6,7-tetrahydrothienoä3,2-cüpyridinderivate als h3-modulatoren
UA92495C2 (ru) Замещенные производные оксадиазола как положительные аллостерические модуляторы метаботропных глутаматных рецепторов

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application